Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 4(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02797119Phase 4Completed

Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery

Role: collaborator

NCT01617018Completed

Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis

Role: collaborator

NCT02245685Completed

Longitudinal Followup of Patients Under Substitution Therapy From the Moment They Enter a Specialized Care Center for Addicts to the Period They Are Monitored by a General Practitioner Outside the Specialized Care Center

Role: collaborator

NCT00235313Phase 4Completed

Adjustment of DOses of NIcotine in Smoking Cessation (ADONIS)

Role: collaborator

NCT00236301Phase 3Terminated

Dose Effects of Hormone Therapy (Two Doses of Estradiol Associated to Progesterone) on Inflammatory Markers

Role: collaborator

All 5 trials loaded